Канада - английски - Health Canada

teva canada limited - theophylline - tablet (extended-release) - 200mg - theophylline 200mg - respiratory smooth muscle relaxants

Канада - английски - Health Canada

teva canada limited - theophylline - tablet (extended-release) - 300mg - theophylline 300mg - respiratory smooth muscle relaxants

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

arpimed llc - salbutamol (salbutamol sulfate) - tablets - 2mg

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

remedica ltd. - salbutamol (salbutamol sulfate) - tablets - 4mg (100/10x10/) in blister

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

arpimed llc - salbutamol (salbutamol sulfate) - tablets - 2mg

Израел - английски - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - syrup - salbutamol as sulfate 2 mg / 5 ml - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types,chronic bronchitis,efmphysema.

Израел - английски - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - tablets - salbutamol as sulfate 2 mg - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types, chronic bronchitis, emphysema.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

rex medical ltd - salbutamol sulfate 0.12mg equivalent to 100 mcg salbutamol - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 0.12mg equivalent to 100 mcg salbutamol excipient: ethanol norflurane oleic acid - salbutamol sulphate is indicated for the prevention and treatment of bronchospasm and acts on the ?2 (beta-2) adrenoceptors of bronchial muscle at therapeutic doses, with little or no action on the ?1 (beta-1) adrenoceptors of the heart. with its fast onset of action, it is particularly suitable for the management and prevention of attack in mild asthma and for the treatment of acute exacerbations in moderate to severe asthma. patients with unstable or severe asthma should not rely on bronchodilators as the main or only form of treatment. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% (predicted at baseline) with greater than 30% variability, usually not returning entirely to normal after a bronchodiliator. together with corticosteroid treatment, salair inhaler provides essential rescue medication for severe asthmatics in treating acute exacerbations. urgent treatment and medical advice is required immediately - if the patient fails to respond rapidly or fully to the rescue medication. salair provides short-acting (4-6 hours) bronchodiliation with fast onset in reversible airways obstruction disease appropriate for emphysema, asthma and chronic bronchitis. it is suitable for long-term use in the relief and prevention of asthma symptoms. salair should be utilized to alleviate symptoms when they happen and to prevent them in those circumstances recognised by the patient to precipitate an asthmatic attack (e.g. before exercise or unavoidable allergen exposure). salair is particularly valuable as rescue medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.

Малта - английски - Medicines Authority

glaxo wellcome uk limited - salbutamol - pressurised inhalation - salbutamol 100 µg - drugs for obstructive airway diseases

Ирландия - английски - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - salbutamol sulfate - nebuliser solution - 1.25/2.5 milligram(s)/millilitre - salbutamol